Pfizer’s RSV Shot to Be Offered to 3 Million More in England

Pfizer Inc.’s vaccine to protect against a potentially dangerous respiratory infection will be offered to about three million more people in England through the state-run National Health Service.

All adults aged 80 and above will be eligible for the vaccine, called Abrysvo, to protect them against respiratory syncytial virus, which can cause bronchitis and pneumonia. The decision announced Thursday expands on an existing program that covered people aged 75 to 79. New evidence shows that vaccination cuts the risk of being hospitalized with the infection by around 75%, the UK Health Security Agency said.